492 related articles for article (PubMed ID: 17709661)
1. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis.
Richmond H; Zwerner J; Kim Y; Fiorentino D
Arch Dermatol; 2007 Aug; 143(8):1025-30. PubMed ID: 17709661
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature.
Mathur K; Morris S; Deighan C; Green R; Douglas KW
J Clin Apher; 2008; 23(4):144-50. PubMed ID: 18633995
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
Prasad SR; Jagirdar J
J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
[TBL] [Abstract][Full Text] [Related]
5. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD
J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.
Moreno-Romero JA; Segura S; Mascaró JM; Cowper SE; Julià M; Poch E; Botey A; Herrero C
Br J Dermatol; 2007 Oct; 157(4):783-7. PubMed ID: 17627792
[TBL] [Abstract][Full Text] [Related]
7. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
Todd DJ; Kagan A; Chibnik LB; Kay J
Arthritis Rheum; 2007 Oct; 56(10):3433-41. PubMed ID: 17907148
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.
Yerram P; Saab G; Karuparthi PR; Hayden MR; Khanna R
Clin J Am Soc Nephrol; 2007 Mar; 2(2):258-63. PubMed ID: 17699422
[TBL] [Abstract][Full Text] [Related]
10. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
11. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
13. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
Khurana A; Greene JF; High WA
J Am Acad Dermatol; 2008 Aug; 59(2):218-24. PubMed ID: 18538448
[TBL] [Abstract][Full Text] [Related]
14. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
Broome DR
Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
Rydahl C; Thomsen HS; Marckmann P
Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
[TBL] [Abstract][Full Text] [Related]
17. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
Andréjak M; Thuillier D; Lok C; Gras-Champel V
Therapie; 2007; 62(2):169-72. PubMed ID: 17582319
[TBL] [Abstract][Full Text] [Related]
18. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
Grobner T; Prischl FC
Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001
[TBL] [Abstract][Full Text] [Related]
19. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
Lim YL; Lee HY; Low SC; Chan LP; Goh NS; Pang SM
Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
[TBL] [Abstract][Full Text] [Related]
20. [Nephrogenic systemic fibrosis].
Breitschaft A; Stahlmann R
Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
